Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma

The aim of this clinical trial is to evaluate the efficacy and safety of consolidation therapy with a neoantigen-loaded dendritic cell vaccine (NeoDC-Vac) following radical chemoradiotherapy or chemoradiation-immunotherapy in patients with locally advanced, unresectable ESCC. The primary endpoint of the study is the OS rate. Secondary endpoints include OS, PFS, adverse events, CR rate, and quality of life (QoL) of patients. Exploratory endpoints involve the assessment of biomarkers such as TMB, PD-L1, and ctDNA. The key questions this study aims to answer are: -Can the combination of (ICIs a

Trial Details

NCT ID
NCT06675201
Phase
PHASE2
Sponsor
Sichuan University
Status
RECRUITING
Cancer Type
Squamous Cell Esophageal Cancer
Interventions
  • neoantigen-loaded dendritic cell vaccine (NeoDC-Vac)
Locations (sample)
  • Chengdu, Please Select, China|30.66667,104.06667

Key Eligibility Criteria

  • A. Age 18-80 years
  • B. Locally advanced unresectable ESCC patients after radical treatment (radical chemoradiotherapy or chemoradiation); including:
  • Cervical esophageal segment, T4, supraclavicular lymph node metastasis, or inability/refusal to undergo surgery due to personal reasons (refer to h…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Squamous Cell Esophageal Cancer Trials on Trialify →